Atossa raises $4.5M in registered direct offering of stock and warrants

ATOSSA THERAPEUTICS, INC.

Sold 1,363,638 shares at $3.30/share plus Series A and B warrants for 1,363,638 shares each at $4.40.
Net proceeds ~$4.1M; expected close June 12, 2026; funds for clinical development and working capital.
Placement agent gets 7% cash fee plus warrants for 123,000 shares at $4.125.
Series A warrants expire in 5.5 years, Series B in 2 years; exercise begins 6 months after issuance.
Potential additional gross proceeds of ~$12M if fully exercised, but no assurance.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

ATOSSA THERAPEUTICS, INC. entered into Purchase Agreement with institutional investors valued at approximately $4.1 million (effective 2026-06-10).

Action: entry
Agreement: equity purchase
Counterparty: institutional investors
Value: approximately $4.1 million
Effective: 2026-06-10

Exact text from the filing

On June 10, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors

View on SEC.gov

801 material agreements filed in the last 30 days. Browse all material agreements →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-266717

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.